Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.

Aleena BanerjiJonathan A BernsteinDouglas T JohnstonWilliam R LumryMarkus MagerlMarcus MaurerInmaculada Martinez-SaguerAndrea ZanichelliJames HaoNeil InhaberMing YuMarc A Riedlnull null

Published in: Allergy (2021)

Lanadelumab demonstrated sustained efficacy and acceptable tolerability with long-term use in HAE patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
randomized controlled trial
open label
clinical trial
angiotensin converting enzyme
patient reported